Last updated: 12 September 2026 · Content curated by Dr. Shabnam Choudhary · Medically reviewed by Dr. Saffiyyah Chaudhary
Quick Answer
Targeted Therapy in India is typically planned at $8,000–$30,000. The stored course is Oral or infusion · months of therapy, but the actual timeline depends on cancer type, treatment intent, the named regimen, number of cycles, response, toxicity and whether later cycles continue at home.
Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply. Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance. The medicine, dose and cycle assumptions must appear in the written estimate; a planning range is not a final hospital quotation.
- India cost range
- $8,000–$30,000
- Typical starting point
- $8,000
- Typical hospital stay
- Oral or infusion · months of therapy
- Treatment timeline
- oral or infusion treatment often continues for months while benefit and tolerance remain
- Recovery
- Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
Major cost factors: target and exact medicine, molecular or receptor testing, originator, biosimilar or generic, duration and resistance. International patients should also budget for accommodation, airport transfers, a medical visa, medicines and follow-up.
Often quoted separately: additional pathology, imaging or molecular testing; extra cycles, dose changes or a new regimen; unlisted supportive medicines and blood products; emergency admission or complication care; travel, lodging and care after return.
Why request a cost through GAF rather than a hospital?
Writing to one campus gets you that campus’s package. A GAF request is reviewed against your records and returned as suitable doctor and hospital options with an indicative, itemised estimate. There is no obligation to book.
- Doctor review first. The number follows a reading of your imaging, test results and clinical records, not a brochure range.
- Hospital options. You can compare listed campuses before you travel, instead of starting over with each international desk.
- International-patient coordination. Visa letters, records routing and companion logistics sit with the same request.
Targeted therapy uses a medicine aimed at a molecular alteration, receptor or signalling pathway that matters to a particular cancer rather than treating all cancers as biologically alike. It may be considered in selected breast, lung, colorectal, melanoma, kidney, gastrointestinal stromal and haematological cancers when a validated target or clinical context supports the drug.
Validated pathology, immunohistochemistry and molecular testing establish whether the target is present. Specimen age, tumour content, previous therapy and disease evolution can determine whether retesting is needed. Treatment names are not prescriptions: pathology, stage, organ function, previous therapy, treatment goals and clinical evidence determine what is appropriate.
Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply. Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
The catalog stores $8,000–$30,000 for India, $80,000–$160,000 for typical US self-pay and Oral or infusion · months of therapy for travel planning. These are comparison bands, not a drug recommendation, treatment guarantee or final quotation.
What Is Targeted Therapy?
Targeted therapy uses a medicine aimed at a molecular alteration, receptor or signalling pathway that matters to a particular cancer rather than treating all cancers as biologically alike.
Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply.
Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
When Is Targeted Therapy Recommended?
It may be considered in selected breast, lung, colorectal, melanoma, kidney, gastrointestinal stromal and haematological cancers when a validated target or clinical context supports the drug.
Finding a mutation does not automatically make a drug useful: the alteration may be non-actionable, the indication unsupported, or resistance may already be present.
How treatment is given, monitored and adapted →
Targeted Therapy cost in India
The $8,000–$30,000 figure is the GAF national planning band for targeted therapy. It may describe consultation, a stated medicine plan, day-care and scheduled monitoring, but it does not establish what one hospital will charge.
Important cost drivers include target and exact medicine, molecular or receptor testing, originator, biosimilar or generic, duration and resistance, medicine-specific monitoring. Medicine acquisition can dominate the invoice, so a quote without drug names, dose and cycle count is not comparable.
No separate Delhi NCR, Mumbai, Bengaluru, Chennai or Hyderabad price is shown unless verified city data exists. This system currently inherits the national band and labels that limitation plainly.
Oral regimens are usually managed through clinic and pharmacy; antibody or other infused regimens use day-care. Admission is reserved for complications, not assumed in the medicine price. For oral therapy, verify legal export, cold-chain needs if any, supply continuity, interaction counselling and who can adjust the dose after the patient returns home.
Targeted Therapy cost breakdown in India
Component prices are rarely published as a public tariff. The lines below describe what typically sits inside a treatment estimate, not a dollar amount for each row.
- Medical oncologist and pathology review
- Confirmation of diagnosis, stage, intent and whether targeted therapy is supported by the available evidence.
- Biomarker or molecular testing when relevant
- Immunohistochemistry, molecular profiling or germline testing only when clinically indicated. Ask whether tissue review and the test itself are included.
- Named anticancer medicines
- The written regimen, dose basis, brand or biosimilar assumption, vial use and number of cycles. A generic 'drug package' is insufficient.
- Infusion or dispensing
- Oral regimens are usually managed through clinic and pharmacy; antibody or other infused regimens use day-care. Admission is reserved for complications, not assumed in the medicine price. Confirm day-care nursing, pharmacy preparation and any oral-drug dispensing fees.
- Supportive medicines
- Anti-nausea treatment, hydration, growth-factor support, infection prevention or blood products only when prescribed and explicitly listed.
- Monitoring and follow-up
- Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance. Confirm which blood tests, scans and consultations sit inside the package window.
Planning range or quotation?
The $8,000–$30,000 figure is an indicative planning range. A final hospital quotation is itemised, issued after a consultant reviews your records, and still subject to what is found clinically.
Get a Personalized Cost Estimate
What is usually included in a Targeted Therapy package?
No two hospitals draw the line in the same place, so read an estimate for what it excludes as carefully as for what it covers. The pattern below is what listed campuses typically bundle into a medical oncology estimate for this treatment. Anything not written into your estimate should be assumed to be extra until the hospital confirms otherwise.
Usually included
Usually included
Named medical-oncology assessment
A consultation tied to the oncologist expected to lead the plan, where bundled.
Usually included
Documented regimen and cycle allowance
The estimate should use the exact treatment name Targeted Therapy and state medicine, dose basis and number of administrations.
Usually included
Quoted medicine and day-care
Only the brands, biosimilars, vials, pharmacy preparation and infusion visits written into the letter are included.
Usually included
Quoted baseline and on-treatment tests
Blood counts, organ-function tests and response imaging only to the extent listed.
Usually included
Quoted supportive care
Anti-emetics, hydration and other prescribed support only when itemized.
May be charged separately
May be separate
Additional pathology, imaging or molecular testing
Repeat biopsy, outside-slide review, NGS or new imaging may be separate when results are incomplete or the disease has changed.
May be separate
Extra cycles, dose changes or a new regimen
Treatment beyond the stated cycle allowance or a switch after progression or toxicity requires a revised estimate.
May be separate
Unlisted supportive medicines and blood products
Growth factors, antimicrobials, transfusions and symptom-control medicines are not automatically bundled.
May be separate
Emergency admission or complication care
Neutropenic fever, severe immune toxicity, dehydration or organ injury can require inpatient care outside a day-care letter.
May be separate
Travel, lodging and care after return
Flights, visas, companion stay, local transport and monitoring by the home oncology team are normally outside the hospital quote.
Catalog inclusions listed for this pathway: medical oncology consultation and records review; named consultant on camera before travel; protocol, cycles and supportive medicines as quoted; on-treatment reviews and toxicity management; discharge summary to your home oncologist.
What can increase the cost?
These are the drivers that actually move a bill for this procedure, in rough order of how often they do it. Most of them are clinical decisions rather than commercial ones, which is why an honest estimate is written after a records review rather than before it.
- Target and exact medicine
- Different molecular targets lead to very different drug prices.
- Molecular or receptor testing
- Tissue adequacy and repeat testing may add cost before any medicine is chosen.
- Originator, biosimilar or generic
- Where alternatives exist, availability and clinical judgement matter.
- Duration and resistance
- Months of therapy and a later drug change drive total cost.
- Medicine-specific monitoring
- Cardiac, eye, liver or other surveillance may sit outside the pharmacy line.
Treatment approaches related to Targeted Therapy
Validated pathology, immunohistochemistry and molecular testing establish whether the target is present. Specimen age, tumour content, previous therapy and disease evolution can determine whether retesting is needed. The rows below are clinical alternatives or neighbouring pathways, not consumer upgrades.
A medical oncologist should explain why the proposed approach fits the pathology and treatment goal, and what result would trigger a change.
Swipe to compare treatment approaches →
| Approach | Relative complexity | GAF planning range | Notes |
|---|---|---|---|
| Molecular Targeted Therapy | Selected by pathology, stage, biomarkers and treatment intent | $10,000–$32,000Catalog planning range | A narrower catalog pathway when a named mutation, fusion or amplification drives selection. |
| Antibody-Drug Conjugate Therapy | Selected by pathology, stage, biomarkers and treatment intent | $25,000–$70,000Catalog planning range | A target-binding antibody carrying a cytotoxic payload; not interchangeable with an oral inhibitor. |
| Precision Oncology | Selected by pathology, stage, biomarkers and treatment intent | $2,000–$7,000Catalog planning range | Testing and interpretation that may — or may not — identify an actionable treatment. |
Planning ranges appear only where GAF Healthcare already publishes a cost sheet for that procedure. Other rows describe relative clinical complexity and should not be read as prices.
Side effects and considerations during Targeted Therapy
Possible effects include rash, diarrhoea, liver-test changes, blood-pressure change, cardiac effects, cytopenias or site-specific toxicity. The pattern belongs to the exact drug, not the word targeted.
Effects vary by medicine, dose, combination, treatment site, previous therapy and individual health. Not every patient experiences every listed effect, and this is not an exhaustive consent list.
The treating medical oncologist should explain expected effects, urgent warning signs, monitoring and when a dose should be held. No page can promise response, cure or a mild treatment course.
Targeted Therapy cost: India vs other medical tourism destinations
India and United States values come from the stored GAF registry. Other rows are explicitly modelled from relative private-care levels and are not official drug tariffs or evidence that a medicine is available.
International comparisons fail when the drug, dose, cycle count, biomarker testing and supportive care differ. Obtain like-for-like written estimates after records review.
Swipe to compare destinations →
| Country | Approximate cost | Relative cost position | Important cost considerations |
|---|---|---|---|
| India | $8,000–$30,000 | Baseline | GAF catalog planning range. The stored India figure is a comparison band. A named medical oncologist must review pathology, stage, biomarkers, dose and cycle assumptions before a hospital issues an itemized estimate. |
| Turkey | $21,000–$34,000Indicative planning estimate* | ≈1.4× India | Private international oncology market. Compare the exact medicines, dose basis, number of cycles, laboratory monitoring and supportive drugs rather than a general cancer package. |
| Thailand | $24,500–$42,000Indicative planning estimate* | ≈1.8× India | Private international hospitals. International desks may coordinate care, but medicine acquisition, biomarker testing, day-care fees and lodging between cycles need written confirmation. |
| United Arab Emirates | $42,000–$68,500Indicative planning estimate* | ≈2.9× India | Regional premium private care. Travel may be shorter for Gulf families; pharmacy, infusion, specialist and monitoring charges may still be billed separately. |
| Singapore | $53,000–$91,000Indicative planning estimate* | ≈3.8× India | High-cost specialist private care. Ask for a self-pay estimate tied to drug names, vial use, dose, cycles and biomarker assumptions rather than a broad medical-oncology label. |
| Germany | $47,500–$85,500Indicative planning estimate* | ≈3.5× India | European specialist oncology care. International access, medicine reimbursement, professional billing and follow-up arrangements vary by centre and patient status. |
| United Kingdom | $42,000–$76,000Indicative planning estimate* | ≈3.1× India | Private self-pay for many visitors. Overseas patients should confirm eligibility, private pharmacy pricing, infusion fees and who manages toxicity after they return home. |
| United States | $80,000–$160,000 | ≈6.3× India | Stored self-pay reference. Hospital, oncologist, laboratory, imaging and drug bills may come from different entities. $80,000–$160,000 is a catalog comparison band, not one bundled quotation. |
*Figures other than India and the United States are modelled planning estimates scaled from the India catalog band, not hospital quotations. All figures are planning information. Cancer type, stage, regimen, drug origin, dose, cycles, tests, supportive care, hospital terms and currency can change the final amount; no row predicts outcome.
The point of this table is not that one country is better. Cost level and treatment-market structure are different things. Compare the named hospital, multidisciplinary support, included care and follow-up pathway as carefully as the headline figure.
Which destination is right for you?
Use this only as a reading guide for the table above. It is not a medical recommendation, and it does not rank countries.
Looking for the lowest overall treatment cost?
IndiaLooking for premium private hospital infrastructure?
Singapore / UAELooking for proximity from the Middle East?
UAE / India / TurkeyLooking for established European oncology systems?
Germany / UK
Why do international patients consider India for targeted therapy?
Some international patients consider India for access to medical oncology review, hospital day-care and a self-pay planning band below typical United States figures. Cost alone is not a reason to travel.
The useful comparison is a named oncologist, evidence-based regimen, medicine source, dose and cycle transparency, toxicity cover and a handover that the home team can continue.
No hospital or clinician is described as best. Urgent disease, poor fitness to fly, unstable complications or funded care near home may make international travel inappropriate.
Hospitals for targeted therapy in India
Hospital cards follow exact live treatment and clinician relationships. Accreditation or a general oncology label does not prove current drug availability, molecular-testing access, treatment volume, clinical-trial access or outcomes.
Indraprastha Apollo Hospital
JCI Accredited
NABH Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
10 listed doctors for this pathway
Languages listed: English, Hindi
Apollo Hospital, Jubilee Hills, Hyderabad
- JCI Accredited
- NABH Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
4 listed doctors for this pathway
Languages listed: English, Telugu, Hindi
Apollo Hospitals, Bannerghatta Road
- JCI Accredited
- NABH Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
6 listed doctors for this pathway
Languages listed: English, Kannada, Hindi
Apollo Hospitals, Navi Mumbai
- JCI Accredited
- NABH Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
2 listed doctors for this pathway
Languages listed: English, Hindi, Marathi
Apollo Proton Cancer Centre
- JCI Accredited
- NABH Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
2 listed doctors for this pathway
Languages listed: English, Tamil, Hindi
Artemis Hospital
- JCI Accredited
- NABH Accredited
- DHADHA
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
1 listed doctor for this pathway
Languages listed: English, Hindi
BLK-Max Super Speciality Hospital
- JCI Accredited
- NABH Accredited
NABL Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
4 listed doctors for this pathway
Languages listed: English, Hindi
Fortis Memorial Research Institute
- JCI Accredited
- NABH Accredited
- NABL Accredited
- Radiation Oncology
- Surgical Oncology
- Medical Oncology
- Hematology
5 listed doctors for this pathway
Languages listed: English, Hindi
Targeted Therapy hospitals in India · Talk to a treatment coordinator
Medical oncologists to consider for targeted therapy in India
Profiles are pulled dynamically only when Targeted Therapy appears in the clinician's current CMS relationships. Verify role, treatment relevance, availability and campus. Placement is not a ranking and this article adds no experience, drug-stock or outcome claim.
Dr. Ajay Sharma
Medical Oncology
18+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
Dr. (Brig) S. Viswanath
Medical Oncology
17+ years Experience
Chemotherapy for Cancer · Cancer Immunotherapy · Targeted Therapy for Cancer
English, Tamil, Hindi
Dr. Bharat Vaswani
Medical Oncology
26+ years Experience
Chemotherapy for Cancer · Cancer Immunotherapy · Targeted Therapy for Cancer
English, Telugu, Hindi
Dr. Darshan R S
Medical Oncology
10+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Kannada, Hindi
Dr. Jeyhan B. Dhabhar
Medical Oncology
5+ years Experience
Chemotherapy for Cancer · Targeted Therapy for Cancer · Cancer Immunotherapy
English, Hindi, Marathi
Dr. Ankur Bahl
Medical Oncology
17+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Hindi
Dr. Arun Ramanan V
Medical Oncology
16+ years Experience
Chemotherapy · Targeted Therapy · Immunotherapy
English, Tamil, Hindi
Dr. Harish Kancharla
Medical Oncology
14+ years Experience
Chemotherapy for Cancer · Cancer Immunotherapy · Targeted Therapy for Cancer
English, Telugu, Hindi
Targeted Therapy doctors in India (80 listed) · Get a personalized cost estimate
Targeted Therapy cost by city in India
Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad inherit the stored India planning band because no verified city-only tariff is held for these Medical Oncology treatments. A national range is not a local quotation.
Doctor and hospital cards resolve only from exact live CMS relationships. This module names no medicine stock, clinical-trial access, volume, rating or outcome, and an empty card area remains visibly empty.
Swipe to compare Indian cities →
Delhi NCR
$8,000–$30,000
India planning band — not a city quote
Typical stay Oral or infusion · months of therapy
No verified Delhi NCR-only tariff is stored for targeted therapy. Use $8,000–$30,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
13 hospitals · 45 doctors
Mumbai
$8,000–$30,000
India planning band — not a city quote
Typical stay Oral or infusion · months of therapy
No verified Mumbai-only tariff is stored for targeted therapy. Use $8,000–$30,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
4 hospitals · 7 doctors
Bengaluru
$8,000–$30,000
India planning band — not a city quote
Typical stay Oral or infusion · months of therapy
No verified Bengaluru-only tariff is stored for targeted therapy. Use $8,000–$30,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
1 hospital · 6 doctors
Chennai
$8,000–$30,000
India planning band — not a city quote
Typical stay Oral or infusion · months of therapy
No verified Chennai-only tariff is stored for targeted therapy. Use $8,000–$30,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
4 hospitals · 9 doctors
Hyderabad
$8,000–$30,000
India planning band — not a city quote
Typical stay Oral or infusion · months of therapy
No verified Hyderabad-only tariff is stored for targeted therapy. Use $8,000–$30,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
5 hospitals · 13 doctors
Costs vary considerably by hospital, specialist, clinical complexity, insurance, room or day-care category, and what is included in the package.
Choosing a city for targeted therapy
Patients usually pick the treating team first and the city second. The city still affects daily travel, accommodation, companion arrangements and access to follow-up. Here is what genuinely differs between the five cities we list.
What should international patients budget beyond the treatment medicine?
A complete targeted therapy budget includes more than the $8,000–$30,000 planning band: pathology reconciliation, tests, medicines, infusion or dispensing, supportive care, monitoring, companion travel, lodging and contingency for a delayed or changed cycle.
Travel should follow written clinical acceptance and an itemized estimate. A visa letter or directory card is not medical clearance.
- Records, pathology and prior-treatment review
- Share biopsy, immunohistochemistry, scans, treatment summaries, medicine doses and toxicity history.
- Biomarker review when relevant
- Confirm whether existing tissue is adequate, whether testing could change the plan, and who interprets the result.
- Regimen and itemized estimate
- Match medicine, dose, cycle count, day-care, tests, supportive drugs and emergency exclusions.
- Arrival and baseline assessment
- Allow time for examination, pathology reconciliation and regimen-specific organ-function tests before the first administration.
- Treatment and monitoring
- Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply. Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
- Handover and return-home plan
- Oral treatment can often continue at home if medicine supply, laboratory monitoring and a local prescriber are secured. An infusion regimen needs a receiving unit that can obtain the same drug. Carry the treatment summary, doses, toxicity record and next monitoring date.
- Treatment episode$8,000–$30,000
- Pre-operative testsOften inside the estimate — confirm
- Hospital stayOral or infusion · months of therapy typically bundled
- Additional procedures or extended careQuoted separately if advised
- Accommodation for companionVaries by city and length of stay
- Local transportationAirport and daily hospital transfers
- FlightsDepends on origin
- Medical visaFee set by the issuing consulate
Planning estimate — not a hospital quotation.
Get a Personalized Treatment Estimate
What does medical travel for targeted therapy in India involve?
The sequence below is how a records-first pathway normally runs. The order matters: everything before arrival exists so that you are not making decisions in an unfamiliar hospital corridor with a suitcase beside you.
Send complete oncology records
Provide pathology, immunohistochemistry, imaging files, prior regimens, dose dates, discharge summaries and molecular reports.
Confirm clinical acceptance
A named medical oncologist reviews diagnosis, intent, evidence, travel safety and whether the hospital can source the proposed medicines.
Hold a remote consultation
Ask why this approach is proposed, what alternatives exist, what remains uncertain and who will manage toxicity.
Compare itemized estimates
Use the same medicine, dose and cycle assumptions; do not compare one vial with a whole course.
Plan flexible travel
Obtain required documents and book refundable travel near the exact campus, with contingency for delayed blood counts or extra review.
Repeat necessary baseline checks
The team may reconcile pathology and repeat laboratory, imaging or organ-function tests before treatment.
Receive treatment
Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply. The plan can change for toxicity, response or new pathology information.
Monitor between administrations
Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
Review fitness to travel
Oral treatment can often continue at home if medicine supply, laboratory monitoring and a local prescriber are secured. An infusion regimen needs a receiving unit that can obtain the same drug.
Continue care at home
Transfer the regimen, doses, adverse-event record and scan schedule to the local team. Monitoring combines medicine-specific toxicity checks with response imaging. At progression, the team may need a new biopsy or molecular test rather than an automatic refill.
Documents to prepare
- Full molecular and immunohistochemistry reports with laboratory details
- Prior targeted medicines and reason for stopping
- Complete pathology report and immunohistochemistry; original slides or blocks if requested
- Recent CT, MRI or PET files rather than phone photographs
- All prior systemic-treatment names, doses, dates and reasons for stopping
- Molecular or germline reports where relevant, including laboratory and specimen details
- Current medicines, allergies, recent blood counts and organ-function tests
Clinical detail
How the treatment is delivered
Validated pathology, immunohistochemistry and molecular testing establish whether the target is present. Specimen age, tumour content, previous therapy and disease evolution can determine whether retesting is needed.
Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply. Commonly discussed approaches include Molecular Targeted Therapy, Antibody-Drug Conjugate Therapy, Precision Oncology.
Oral regimens are usually managed through clinic and pharmacy; antibody or other infused regimens use day-care. Admission is reserved for complications, not assumed in the medicine price. Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
Main variations
- Molecular Targeted Therapy
- A narrower catalog pathway when a named mutation, fusion or amplification drives selection.
- Antibody-Drug Conjugate Therapy
- A target-binding antibody carrying a cytotoxic payload; not interchangeable with an oral inhibitor.
- Precision Oncology
- Testing and interpretation that may — or may not — identify an actionable treatment.
Preparation
Validated pathology, immunohistochemistry and molecular testing establish whether the target is present. Specimen age, tumour content, previous therapy and disease evolution can determine whether retesting is needed. Send complete reports and imaging files rather than a photograph of a prescription.
Before treatment, the team may repeat blood counts, kidney or liver tests, infection screening, cardiac assessment or pregnancy testing according to the proposed medicine. These are regimen-specific, not universal.
Hospital stay and recovery
Oral regimens are usually managed through clinic and pharmacy; antibody or other infused regimens use day-care. Admission is reserved for complications, not assumed in the medicine price. Possible effects include rash, diarrhoea, liver-test changes, blood-pressure change, cardiac effects, cytopenias or site-specific toxicity. The pattern belongs to the exact drug, not the word targeted.
Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
The catalog's Oral or infusion · months of therapy is a broad planning guide, not a promise that the patient can fly or stop monitoring on a fixed date.
Monitoring combines medicine-specific toxicity checks with response imaging. At progression, the team may need a new biopsy or molecular test rather than an automatic refill. Seek urgent clinical help for fever, breathing difficulty, new confusion, severe diarrhoea, uncontrolled vomiting, bleeding or any warning sign specified by the treating team.
How to compare Targeted Therapy quotes from Indian hospitals
Print these and work through them on the video call. A house that answers without hedging is telling you something useful about how it will behave when something goes wrong.
- Why is targeted therapy being considered now, and what alternatives were discussed?
- Has the pathology been reviewed, and is the stage current?
- Is biomarker, molecular or germline testing clinically relevant, and is it included?
- Who is the named medical oncologist, and at which exact campus is treatment delivered?
- Are pathology-review charges included, and are original slides or blocks needed?
- Which medicines, brands or biosimilars are quoted?
- How is the dose calculated, and how many cycles or months are included?
- Are pharmacy preparation, infusion day-care and nursing included?
- Are anti-nausea medicines, hydration and other supportive medicines included?
- Are growth factors or blood products included if prescribed?
- Which blood tests and scans are included?
- What is charged if the dose is held, reduced or changed?
- What happens if additional cycles are recommended?
- Are emergency admission and complication care excluded?
- Are any planned hospital-admission or observation charges included?
- Can later cycles or monitoring continue safely at home?
- Which follow-up consultation and written handover are included?
- What costs are explicitly excluded from the treatment package?
- Which documented target supports this medicine?
- How many weeks or cycles of medicine, dispensing and monitoring are included?
Frequently asked questions
How much does targeted therapy cost in India?
Targeted Therapy is typically planned at $8,000–$30,000. This is a stored comparison range, not a quotation; medicine, dose, cycles, testing and hospital terms determine the final amount.
What is targeted therapy?
Targeted therapy uses a medicine aimed at a molecular alteration, receptor or signalling pathway that matters to a particular cancer rather than treating all cancers as biologically alike.
When is targeted therapy considered?
It may be considered in selected breast, lung, colorectal, melanoma, kidney, gastrointestinal stromal and haematological cancers when a validated target or clinical context supports the drug.
Does every patient with this cancer need the same treatment?
Finding a mutation does not automatically make a drug useful: the alteration may be non-actionable, the indication unsupported, or resistance may already be present. Selection requires individual medical-oncology and multidisciplinary review.
Do biomarker or molecular tests affect treatment selection?
Validated pathology, immunohistochemistry and molecular testing establish whether the target is present. Specimen age, tumour content, previous therapy and disease evolution can determine whether retesting is needed.
How is the treatment given?
Some targeted medicines are tablets taken daily; others are injections or infusions on repeating schedules. Oral treatment still needs prescribing, interaction checks, toxicity monitoring and reliable supply.
How long does targeted therapy take?
oral or infusion treatment often continues for months while benefit and tolerance remain. Oral or infusion · months of therapy is the catalog travel-planning assumption, not a fixed course.
Are anticancer medicines included in the hospital package?
Only medicines named in the itemized estimate are included. Confirm the drug, brand or biosimilar, dose, vial use and cycle allowance.
What can make the quotation change?
Important drivers include target and exact medicine, molecular or receptor testing, originator, biosimilar or generic, duration and resistance, medicine-specific monitoring.
What monitoring is usually needed?
Blood tests, blood pressure, ECG or cardiac imaging, skin review, eye review or other tests depend on the medicine. Interval scans assess response and emerging resistance.
Can the regimen change after arrival?
Yes. Pathology review, examination, organ function, toxicity or new imaging can change the medicine, dose or timing. The hospital should revise the estimate in writing.
How should an international patient choose a medical oncologist?
Verify the clinician's role, exact procedure relationship, proposed regimen, communication, toxicity cover and handover. Directory placement is not a ranking.
Can later treatment continue after returning home?
Oral treatment can often continue at home if medicine supply, laboratory monitoring and a local prescriber are secured. An infusion regimen needs a receiving unit that can obtain the same drug.
What follow-up is required?
Monitoring combines medicine-specific toxicity checks with response imaging. At progression, the team may need a new biopsy or molecular test rather than an automatic refill.
Dr. Shabnam Choudhary, BDS, is a dental professional who graduated from Al-Ameen Medical College, Bijapur, Karnataka. She contributes to the curation and development of medically informative healthcare content, helping ensure that information is structured clearly and presented in a patient-friendly manner.
Content Curator
Dr. Shabnam Choudhary
BDS
Al-Ameen Medical College, Bijapur, Karnataka
Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru
Dr. Saffiyyah Chaudhary, BDS, is a dental professional who graduated from Al-Ameen Medical College, Bijapur, Karnataka. She provides medical review of healthcare content to help ensure that clinical information is accurate, understandable, and appropriately presented for patients and their families.
Medically Reviewed By
Dr. Saffiyyah Chaudhary
BDS
Al-Ameen Medical College, Bijapur, Karnataka
Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru
Related treatment costs
Molecular Targeted Therapy cost in India
$10,000–$32,000 · stay Oral or infusion by mutation
Precision Oncology cost in India
$2,000–$7,000 · stay NGS panel + clinic visit
Antibody-Drug Conjugate Therapy cost in India
$25,000–$70,000 · stay Infusion day-care · weeks to months
Immunotherapy cost in India
$15,000–$45,000 · stay Outpatient q2–6 weeks
Cost note
Cost ranges on this page are for preliminary planning and comparison only. The final treatment cost depends on the patient's diagnosis, treatment plan, hospital, doctor, procedure complexity and other clinical factors. A personalized quotation should be obtained before making treatment or travel decisions.
This page is general information about treatment costs and pathways. It is not a diagnosis, a treatment recommendation or a substitute for an individualised medical opinion. Decisions about whether this procedure is appropriate for you belong to a qualified doctor who has reviewed your records.
Last updated 12 September 2026. Cost data is maintained separately from this article and refreshed as listed campuses revise their planning ranges.
Targeted Therapy cost sheet · All treatment costs in India · Medical Oncology costs
